The purpose of this study being conducted at the Masonic Cancer Centre at the University of Minnesota is to develop the clinical standard of care for patients with a solid cancer that has a high risk of relapse. Following intensive chemotherapy, the patients in the treatment group will be injected with bone marrow derived stem cells. The primary outcome measure is an improvement in overall survival and disease-free rates. The study commenced in October 2011 and expects to recruit 20 subjects. It is expected to be completed by December 2016.